Last updated: 15 June 2019 at 1:38am EST

Patrick M Wheeler Net Worth




The estimated Net Worth of Patrick M Wheeler is at least $254 Thousand dollars as of 18 September 2014. Patrick Wheeler owns over 8,246 units of ARCA biopharma Inc stock worth over $243,624 and over the last 15 years Patrick sold ABIO stock worth over $10,802.

Patrick Wheeler ABIO stock SEC Form 4 insiders trading

Patrick has made over 1 trades of the ARCA biopharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Patrick sold 8,246 units of ABIO stock worth $10,802 on 18 September 2014.

The largest trade Patrick's ever made was selling 8,246 units of ARCA biopharma Inc stock on 18 September 2014 worth over $10,802. On average, Patrick trades about 1,649 units every 0 days since 2010. As of 18 September 2014 Patrick still owns at least 101,510 units of ARCA biopharma Inc stock.

You can see the complete history of Patrick Wheeler stock trades at the bottom of the page.



What's Patrick Wheeler's mailing address?

Patrick's mailing address filed with the SEC is C/O ARCA BIOPHARMA, INC., 8001 ARISTA PLACE, SUITE 200, BROOMFIELD, CO, 80021.

Insiders trading at ARCA biopharma Inc

Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.



What does ARCA biopharma Inc do?

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.



What does ARCA biopharma Inc's logo look like?

ARCA biopharma Inc logo

Complete history of Patrick Wheeler stock trades at ARCA biopharma Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Sep 2014 Patrick M Wheeler
acting Chief Financial Officer
Sale 8,246 $1.31 $10,802
18 Sep 2014
101,510


ARCA biopharma Inc executives and stock owners

ARCA biopharma Inc executives and other stock owners filed with the SEC include: